INLEXZO vs ONUREG

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated June 7, 2026·How we rate

Possible drug interaction. INLEXZO and ONUREG are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	INLEXZO	ONUREG
Rating	New	New
Pharmacy pays	~$599.88 /30	—
Type	RX	RX
Active ingredient	GEMCITABINE HYDROCHLORIDE	AZACITIDINE
Manufacturer	Janssen Biotech	Bristol
Dosage forms	System	Tablet
Drug class	Nucleoside Metabolic Inhibitor	Nucleoside Metabolic Inhibitor
Boxed warning	None	None
Treats	Breast Neoplasms, Non-Small-Cell Lung Carcinoma, Ovarian Neoplasms	Refractory Anemia, Sideroblastic Anemia, Chronic Myelomonocytic Leukemia

inlexzo onureg

Rating

New

Pharmacy pays

~$599.88 /30

—

Type

Active ingredient

GEMCITABINE HYDROCHLORIDE

AZACITIDINE

Manufacturer

Janssen Biotech

Bristol

Dosage forms

System

Tablet

Drug class

Nucleoside Metabolic Inhibitor

Boxed warning

None

Treats

Breast Neoplasms, Non-Small-Cell Lung Carcinoma, Ovarian Neoplasms

Refractory Anemia, Sideroblastic Anemia, Chronic Myelomonocytic Leukemia

Frequently asked questions

What is the difference between Inlexzo and Onureg?

Inlexzo contains Gemcitabine Hydrochloride, while Onureg contains Azacitidine — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.